^
Association details:
| Biomarker: | TP53 mutation + ARID1A mutation |
|---|---|
| Cancer: | Non-Hodgkin’s Lymphoma |
| Drug Class: | CAR-T immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
Impact of ARID1A and TP53 mutations in pediatric refractory or relapsed mature B-Cell lymphoma treated with CAR-T cell therapy
Published date:
11/19/2023
Excerpt:
CAR-T cell treatment significantly improved survival in r/r MB-NHL patients (P = 0.00081), but patients with ARID1A or ARID1A and TP53 co-mutation had poor survival compared to those without such mutations….These results indicate that children with MB-NHL harboring ARID1A or TP53 and ARID1A co-mutation are insensitive to initial conventional chemotherapy and subsequent CAR-T cell treatment.
DOI:
10.1186/s12935-023-03122-2
